Results 161 to 170 of about 121,257 (309)

Secular Trend in Glycaemic Management in Type 2 Diabetes Patients With and Without Cirrhosis Between 2000 and 2023: A Territory‐Wide Cohort Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In this territory‐wide cohort study, improving glycemic control can be observed regardless of cirrhosis status. Oral antidiabetic medication was more often used in the non‐cirrhosis group, and insulin was preferred in patients with decompensated cirrhosis, who exhibited an increasing incidence of hypoglycemia over the years and need individualized ...
Mary Yue Wang   +6 more
wiley   +1 more source

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms

open access: yesBritish Journal of Pharmacology, EarlyView.
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl   +3 more
wiley   +1 more source

Mind the gap: Ongoing inequalities in glycaemic levels in young people living with Type 1 diabetes across England and Wales

open access: yesDiabetic Medicine, EarlyView.
Inequalities in glycaemic outcomes for young people living with Type 1 Diabetes in England and Wales. Abstract Aims Inequalities in glycaemic levels in children and young people (CYP) living with Type 1 diabetes (T1D) across different ethnic and socio‐economic groups in England and Wales were first highlighted in 2016.
Victoria Homer   +6 more
wiley   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo   +4 more
wiley   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy